DB17601InvestigationalCell transplant therapies
Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.
What you can answer from here — as of April 23, 2025
Which companies are running trials of Ixmyelocel-T, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account